Stay updated on Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page.

Latest updates to the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check25 days agoChange DetectedPage now reflects a new software/operational revision (v3.2.0) and includes a government-funding status notice, replacing the previous v3.1.0 and its associated wording.SummaryDifference2%

- Check32 days agoChange DetectedPage revision updated from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.0%

- Check39 days agoChange DetectedThe item/service availability has been reversed from Available to No longer available, indicating it is no longer offered.SummaryDifference0.1%

- Check46 days agoChange DetectedStandardizes regional naming to 'Tatarstan, Respublika' and updates the Kazan address accordingly (v3.0.2); removes the 'Back to Top' link as a minor UI cleanup.SummaryDifference0.2%

- Check53 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.1%

- Check60 days agoChange DetectedThe webpage has been updated with new facility names and locations, including specific cities and countries, as well as a new publication related to telisotuzumab vedotin. Additionally, the page now includes a new date for an estimated last update.SummaryDifference27%

Stay in the know with updates to Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page.